TREATMENT OF FIBROCYSTIC DISEASE OF BREAST WITH A PROLACTIN INHIBITOR - 2-BR-ALPHA-ERGOCRYPTINE (CB-154)

  • 1 January 1976
    • journal article
    • research article
    • Vol. 48  (6) , 703-706
Abstract
In order to evaluate the importance of prolactin in the pathogenesis and clinical evolution of fibrocystic disease of the breast, serum prolactin levels were determined in 7 patients affected by this condition before and during treatment with a prolactin inhibitor, 2-Br-.alpha.-ergocryptine (CB-154). Serum prolactin levels were low or normal before treatment. During treatment with CB-154 there was an improvement in all patients but 2. Although no conclusion on the possible relation between serum prolactin levels and fibrocystic disease of the breast was found CB-154 may be useful for treating patients with this disorder.

This publication has 0 references indexed in Scilit: